5-10% of the world’s population suffer from asthma. That’s over 23 million people, 7 million of whom are children. Whilst for some it is a minor nuisance, asthma can be a chronic and often debilitating problem and can be a precursor to numerous comorbidities. The condition causes the airways to narrow and potentially produce more
Read More
Investors that missed out on the IPO for medtech company 4D Medical (ASX: 4DX) have had no qualms buying the stock on market with shares in 4DX opening at $1.47 when trading commenced this morning, more than double the IPO Offer Price of $0.73. The significant jump follows a similar trend among Australian investors that
Read More
Under new management, medtech company Respiri (ASX: RSH) is poised to enter the lucrative SaaS revenue market by leveraging their asthma screening device to partner with Phenix Healthcare, whose patients will be able to monitor their condition using Respiri’s wheezo device. The agreement will give Phenix Healthcare’s patients diagnosed with asthma an option to monitor
Read More